Introduction
c-Met is the prototypical member of a subfamily of RTKs, which also includes Recepteur d'origine nantais (RON) kinase. Hepatocyte growth factor (HGF), also known as scatter factor (SF), is the only known high-affinity ligand of c-Met (4) . Under physiological conditions, c-Met is mainly activated by its ligand, HGF, in a paracrine fashion (4) (5) , and is tightly regulated by ligand concentration and activation at the target cell surface, and ligand activated receptor internalization and degradation. Activation of the c-Met pathway provides a powerful signal for cell survival, migration and proliferation (invasive growth), which is critical during embryonic development and wound healing (6) (7) .
It is now widely accepted that the c-Met signaling that nourishes the early development and tissue regeneration is aberrantly activated in cancer cells and can lead to the neoplastic dissemination of tumors (7) (8) . The propagation of c-Met-dependent invasive growth signals has been shown to be a general and important feature of highly aggressive tumors (9) (10) . In most cancers, c-Met and HGF are overexpressed relative to surrounding tissues, and their expression correlates with poor patient prognosis (11) (12) . In these cases, aberrant c-Met activation is reported to occur through transcriptional upregulation by various mechanisms including 1) other oncogenes such as Ras (13) and β-Catenin (14) , 2) environmental conditions such as hypoxia (15) or 3) molecules generated by the reactive stroma of full-blown tumors such as inflammatory 4 cytokines, growth factors (including HGF itself) and pro-angiogenic factors (16) (17) (18) . In many of these tumors c-Met activation is a secondary event--the consequence rather than the cause of the malignant phenotype, and it serves as a co-activated oncogene that further exacerbates the malignant properties of already transformed cells by conveying its anti-apoptotic, proliferative, angiogenic and unique pro-invasive signals to support tumor cells in overcoming selective pressures during cancer metastatic progression (19) (20) .
In contrast to its role in promoting tumor invasive growth and metastasis in a wide range of cancers, a small subset of cancers where MET gene amplification has been identified become 'addicted' to c-Met pathway activation. Amplification of the MET gene locus, with consequent protein overexpression and constitutive kinase activation, has been reported in patients with gastric, metastatic colorectal cancer, esophageal adenocarcinoma, medulloblastoma (21) (22) (23) (24) and non-small-cell lung carcinomas (NSCLC) with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors (25) . In these tumor models, c-Met inhibition results in a proliferative blockage and/or marked cell death, and subsequent tumor regression (26) (27) (28) .
Other mechanisms of c-Met mediated oncogenic pathway activation include MET gene mutation and aberrant autocrine ligand production. c-Met-activating point mutations in the kinase domain are implicated as the cause of hereditary papillary renal carcinoma and were also detected in sporadic papillary renal carcinoma, lung cancers, head and neck cancers, childhood hepatocellular carcinoma, and gastric cancer (29) (30) (31) (32) (33) . Aberrant activation of c-Met by expressing both HGF and c-Met (HGF/c-Met autocrine loop formation) in tumor cells was also described for glioblastomas, breast carcinomas, rhabdomyosarcomas and osteosarcomas (34) (35) (36) (37) . 
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(100 ng/mL) and incubated at 37 °C for 48-72 h. MTT (Promega) or Resazurin (Sigma) assays were performed to determine the relative cell numbers.
Tumor cell migration and matrigel invasion assays.
NCI-H441 cell and HUVEC migration/invasion were determined using the ACEA RT-CIM System (ACEA Biosciences) following the manufacture's instructions.
Apoptosis assay. GTL-16 cells were seeded in 96 well plates at 40,000 cells/well. Designated concentrations of PF-04217903 or vehicle were added to the wells in serum free media. Cells were incubated in 37°C, 5% CO 2 for 48 h. The ssDNA Apoptosis ELISA kit (Chemicon International) was used following manufacturer's instructions.
In Vivo Studies
Animals: Female nu/nu mice were obtained from Charles River (Wilmington, MA). Animals 
Results

PF-04217903 Potently Inhibited the Catalytic Activity of c-Met and its Oncogenic
Mutants in Vitro
PF-04217903 (Structure, Supplementary Fig. S1 ) was identified as a potent ATP-competitive inhibitor of the catalytic activity of recombinant, human c-Met kinase with a mean Ki of 4.8 nM.
In cell based assays, PF-04217903 inhibited HGF-stimulated or constitutive total tyrosine phosphorylation of wild type c-Met with a mean IC 50 growth in vitro, significant tumor growth inhibition (TGI) was achieved in all five dose groups, with 10mg/kg and 30mg/kg dose levels demonstrating marked tumor size reduction of 68% and 84% respectively ( Figure 3A ). This dose-dependent TGI correlated with the decreased Ki67 expression in these tumors determined by IHC analysis (Fig. 3C) . Phospho-RTK array analysis showed that besides c-Met, EGFR and PDGFRβ were also co-activated in U87MG xenograft tumors (data not shown). To investigate the mechanisms underlining the observed antitumor efficacy in this model, we conducted Western blot analysis with tumor lysates to assess the status of the three co-activated RTKs (c-Met, EGFR and PDGFR) as well as RTK downstream signaling. As shown in Figure 3B , 5 hours (Tmax) after oral dosing, PF-04217903 dosedependently inhibited c-Met, Gab1, Erk1/2, and Akt phosphorylation, and induced apoptosis (cleaved caspase3) in U87MG xenograft tumors at all dose levels (5 mg/kg, 15 mg/kg and 50 mg/kg, PO/QD for 3 days). In addition, there was no significant change in phospho or total EGFR levels associated with PF-04217903 treatment in this study, but interestingly a strong and dose-dependent induction in phospho PDGFRβ levels were observed (Fig 3D) .
Antitumor efficacy of PF-04217903 in human xenograft models exhibiting c-Met overexpression.
c-Met is highly expressed in almost every type of cancer (2) . To investigate the relationship (Fig. 4C ) and resulted in a 45% TGI (Fig. 4B) . The same dosing regimen of PF-04217903 in SW480 tumors had no effect on tumor growth (Fig 4B) suggesting elevated c-Met expression may also be an important factor for tumor response. Furthermore, following 27 days of PF-04217903 treatment, c-Met total protein levels in SW620 increased significantly as shown by Western blot analysis (Fig 4C) . This 
express c-Met, by 44%, 43% and 39% respectively (Fig 4G-I) . Collectively, these results indicate near complete inhibition of c-Met activity by PF-04217903 in the selected c-Met overexpressing models resulted in significant but incomplete tumor growth inhibition. PF-04217903 was well tolerated in mice. There was no animal body weight loss observed in any of the dose levels tested in the vivo studies.
Anti-angiogenic effects of PF-04217903 in vitro and in vivo
HGF/c-Met pathway is known to promote tumor angiogenesis therefore fostering cancer progression (1,2,41). PF-04217903 was evaluated for its anti-angiogenic activity in vitro and in vivo.
PF-04217903 inhibited HGF stimulated c-Met phosphorylation in Human Umbilical
Vascular Endothelial Cells (HUVEC) with an IC 50 value of 4.6 nM (Supplement Table 1 ). In endothelial cell functional assays, PF-04217903 inhibited HGF-mediated HUVEC survival (IC 50 = 12 nM), matrigel invasion (IC 50 = 27 nM) and induced HUVEC apoptosis (IC 50 = 7 nM) ( Table   1 ). PF-04217903 was evaluated for modulation of microvessel density (MVD) assessed by immunostaining for CD31 (platelet endothelial cell adhesion molecule 1) in vivo. A significant reduction of CD31-positive endothelial cells was observed at 3, 10, and 30 mg/kg/day in U87MG tumors following 10-days of PF-04217903 treatment (Fig. 5A) indicating that inhibition of MVD correlated to significant antitumor efficacy (Fig 3A) . c-Met and HGF have also been shown to regulate the secretion of pro-angiogenic factors, including VEGFA and IL-8 by tumor cells (16) (17) (18) . Therefore, the effect of PF-04217903 on VEGFA and IL-8 plasma levels was assessed. In these studies, PF-04217903 showed a significant dose-dependent reduction of human IL-8 levels in both the U87MG and GTL-16 models (Fig 5B-C) , and decreased human VEGFA levels in the GTL-16 model (Fig 5C) . This data suggests that the anti-angiogenic 
activity of PF-04217903 could be mediated either through direct effect in endothelial cells and/or through reduced secretion of proangiogenic factors by tumor cells.
Discussion
In this report we described a novel ATP competitive, potent and highly selective small molecule inhibitor of c-Met. The antitumor efficacy of PF-04217903 was also evaluated in tumor models that 1) harbor MET gene amplification, 2) exhibit a HGF/c-Met autocrine loop or 3) express high levels of c-Met. Because it is highly selective against c-Met, PF-04217903 is an ideal tool to study the consequences of specifically perturbing c-Met catalytic activity in various cancer models without the perplexing effects of off-target kinase inhibition. Therefore, the antitumor efficacy following PF-04217903 treatment is most likely exclusively mediated by inhibiting c-Met activity in the tumor models tested. 
and Ron therapy demonstrated a therapeutic benefit of the combination approach for c-Met inhibitors in c-Met overexpressing cancers. Since the HT29 tumor also expresses a high level of activated EGFR, we included a treatment group with erlotinib as a single agent in the same HT29 study and achieved 55% TGI (data not shown), which is similar to that observed with Ron shRNA alone (52%), indicating that EGFR also played a partial role in sustaining HT29 tumor growth. Collectively, our results suggest that although c-Met overexpression alone is not a biomarker for c-Met "oncogene addiction", the elevated c-Met level might be a prerequisite for A.
